Abstract
Cancer is a broad term for many disparate diseases with different etiologies, commonly classified by affected organ site. This review summarizes the published evidence from prospective cohort studies examining the associations between vitamin D, measured as serum 25-hydroxyvitamin D (25OHD) concentrations, and the risk of rarer cancer sites including pancreatic, non-Hodgkin lymphoma, ovarian, endometrial, kidney, gastric and esophageal cancer. Overall, evidence from prospective cohort studies provides little support for a protective association between adequate or higher serum 25OHD concentrations and risk of these rarer cancer sites. Additionally, controversy persists concerning a potential increased risk of pancreatic cancer associated with serum 25OHD levels >100 nmol/L due to conflicting results reported by two large prospective pooling projects.
Keywords: 25-hydroxyvitamin D, Bladder cancer, Cancer, Cohort, Endometrial cancer, Esophageal cancer, Gastric cancer, Kidney cancer, Nested case-control study, Non-Hodgkin lymphoma, Ovarian cancer, Pancreatic cancer, Prospective studies, Vitamin D
Anti-Cancer Agents in Medicinal Chemistry
Title:Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers
Volume: 13 Issue: 1
Author(s): Kathy J. Helzlsouer and Lisa Gallicchio
Affiliation:
Keywords: 25-hydroxyvitamin D, Bladder cancer, Cancer, Cohort, Endometrial cancer, Esophageal cancer, Gastric cancer, Kidney cancer, Nested case-control study, Non-Hodgkin lymphoma, Ovarian cancer, Pancreatic cancer, Prospective studies, Vitamin D
Abstract: Cancer is a broad term for many disparate diseases with different etiologies, commonly classified by affected organ site. This review summarizes the published evidence from prospective cohort studies examining the associations between vitamin D, measured as serum 25-hydroxyvitamin D (25OHD) concentrations, and the risk of rarer cancer sites including pancreatic, non-Hodgkin lymphoma, ovarian, endometrial, kidney, gastric and esophageal cancer. Overall, evidence from prospective cohort studies provides little support for a protective association between adequate or higher serum 25OHD concentrations and risk of these rarer cancer sites. Additionally, controversy persists concerning a potential increased risk of pancreatic cancer associated with serum 25OHD levels >100 nmol/L due to conflicting results reported by two large prospective pooling projects.
Export Options
About this article
Cite this article as:
J. Helzlsouer Kathy and Gallicchio Lisa, Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1871520611307010065
DOI https://dx.doi.org/10.2174/1871520611307010065 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery Mucosal T Cell Proliferation and Apoptosis in Inflammatory Bowel Disease
Current Drug Targets Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Current Drug Metabolism Diabetic Gastroenteropathy: Soothe the Symptoms or Unravel a Cure?
Current Diabetes Reviews The Effect of Alcohol on Gastrointestinal Motility
Reviews on Recent Clinical Trials Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry An Overview of the Design, Development and Applications of Biodegradable Stents
Drug Delivery Letters Effective Inhibition of Mitochondrial Metabolism by Cryptotanshinone in MDA-MB231 cells: A Proteomic Analysis
Current Proteomics Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Mentha L. Species (Lamiaceae) as Promising Sources of Bioactive Secondary Metabolites
Current Pharmaceutical Design Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry Enzymatic regulation and functional relevance of NOX5
Current Pharmaceutical Design Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs)
Anti-Cancer Agents in Medicinal Chemistry Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design